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Carboxyl groupa b s t r a c t
The ﬂuoroquinolone antibiotic binding site in the hERG potassium channel was examined for the residues
involved and their position in the tetrameric channel. The blocking effect of the two ﬂuoroquinolones lev-
oﬂoxacin and sparﬂoxacin to tandem dimers of the hERG mutants were evaluated electrophysiologically.
The results indicated that two Tyr652s in the neighboring subunits and one or two Phe656s in the diag-
onal subunits contributed to the blockade in the case of both compounds, and Ser624 was also involved.
The docking studies suggested that the protonated carboxyl group in the compounds strongly interacts
with Phe656 as a p acceptor.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.The long QT syndrome (LQTS) is a disorder of ventricular repo-
larization that predisposes affected individuals to cardiac arrhyth-
mia and sudden death. It has long been clinically recognized that
drug-induced LQTS is a serious side effect, and the cardiac hERG
potassium channels have been related to this QT prolongation.1
In fact, drugs such as terfenadine and cisapride block the hERG
channel to deleterious effect and thus have been withdrawn from
the market. Thus, designing drugs without side effects to the hERG
channel has been a critical issue in drug development.2
In the absence of the crystal structure for the hERG channel,
systematic studies of drug synthesis have accumulated informa-
tion on ligand-based empirical rules that has provided hints for
designing drugs without the hERG liability. The approaches in-
clude: pKa reduction,3 controls of logP4 and logD,5 a zwitterion ap-
proach,6 and introduction of an acidic substituent.7
Among these, the acidic substituent has been demonstrated to
be effective for the reduction of hERG side-effects. For example,
Zhu et al. reported a substantial reduction in the level of hERG
blockade by incorporating a carboxylic acid into Factor Xa inhibi-
tors.8 On the other hand, ﬂuoroquinolone antibiotics, even when
possessing a carboxyl group in their structures,9,10 have beenreported to block hERG. Alexandrou et al. demonstrated that the
blocking effect of the ﬂuoroquinolone antibiotic moxiﬂoxacin
was mediated by the binding to the pore, especially at the Ty652
site.11 These conﬂicting effects of the carboxyl group raised a ques-
tion as to how the relevant chemical group plays a role in the bind-
ing of drugs to the hERG channel.
The hERG channel is a homotetrameric protein, while most
drugs having the hERG-blocking activity interact with the hERG
channel via a one-to-one stoichiometry, indicating that a given
drug interacts with multiple subunits. The drug binding site is lo-
cated in the central cavity, the inner surface of which is lined by
hydrophobic residues from the four subunits. When a point muta-
tion is introduced, the functional channel bears four mutated resi-
dues in four symmetrical positions, and examining the speciﬁc
interactions between the reactive sites of the drug and amino acid
residues of the channel have proven to be elusive as far as conven-
tional mutational approaches are used.
Here we focus on the binding interaction of ﬂuoroquinolone
with the hERG channel through a synergic approach.12 To elucidate
the number and relative positions of the residues required for the
binding, we constructed a tandem dimer of the hERG channel by
linking two hERG molecules.13 The two hERG molecules are con-
catenated so as to form the tandem dimer, which is assembled into
a functional channel as a dimer of the tandem dimers. The channel
formed by the tandem dimers exhibits similar functional features
as that of the wild-type (WT), involving the activation and inacti-
vation gating and the drug binding afﬁnity.13 When a point
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the functional channel bears two mutated sites in the diagonal
subunits and breaks the fourfold symmetry. Thus, the interactions
between drugs and channel residues in different arrangements can
be investigated.
Mutations were introduced into the Ser624, Tyr652 and Phe656
sites, which have been established as important for drug binding.14
The binding afﬁnities towards a set of tandem mutants, including
the WT and the homo-tetrameric mutants, were examined electro-
physiologically for the two ﬂuoroquinolone antibiotics, levoﬂoxa-
cin and sparﬂoxacin. These results demonstrated the number and
relative positions of the contributing residues. This information
guided us in building docking models from the limited number
of the initial positions of the drug at the binding site. The proposed
binding modes for ﬂuoroquinolone antibiotics revealed a speciﬁc
interaction between the carboxyl group and Phe656. The effect of
protonation on the carboxyl group is discussed.
The blocking effects of ﬂuoroquinolones were evaluated by
measuring the hERG currents using the patch-clamp method. Six
types of channels were expressed in HEK 293 cells; WT, homo-tet-
rameric mutants (S624A, Y652A and F656A) and tandem dimeric
mutants (Y652A and F656A). Electrolyte solutions containing dif-
ferent concentrations of ﬂuoroquinolone were perfused, and the
current was monitored periodically. After the drug blockade
reached a steady-state, the current was measured under a volt-
age-clamp condition (depolarized to +10 mV for 500 ms). The peak
amplitudes of the tail current were measured upon repolarization
to 40 mV for most of the channels (Fig. 1A and C), and to
120 mV for the F656A-containing mutants (Fig. 1B and D) such
that the peak amplitude was clearly resolved.12 The current ampli-
tudes were normalized to those obtained in the absence of the drug
(Idrug/Icontrol), and they were plotted as a function of the drug con-
centration (Fig. 1).
For levoﬂoxacin, the drug-inhibition curves are shown sepa-
rately for the mutations in the Y652 site (A) and the F656 site
(B), and the IC50 values and the Hill coefﬁcients are shown in the
right column. The S624mutation results were included in Figure 1AA B
C D
Figure 1. Concentration-dependent blockade of WT and mutant hERG channels by levoﬂ
A and C, and at 120 mV for B and D. IC50 and the Hill coefﬁcient are shown in the righfor comparison. F656A designates a homo-tetrameric mutant with
all four F656s replaced, while td(WT: F656A) indicates that only
two F656s in the diagonal subunits were replaced. Each ﬁgure
shows the shifts of the drug-inhibition curves for the different mu-
tants involving a different number of the mutated residues. The
F656A curve in Figure 1B indicates that the F656 residues contrib-
ute substantially for the drug binding. On the other hand, nearly
identical curves for the WT and td(WT: F656A) mutant indicate
that the four F656s are not all necessary for the binding, but rather,
at most only two residues in diagonally positioned subunits con-
tribute to the binding. The similar pattern of the shift of the
drug-inhibition curves were observed for sparﬂoxacin (Fig. 1D).
In contrast to the effects of the F656 mutants, Figure 1A and C
shows that deleting two diagonal Y652s (td(WT: Y652A)) signiﬁ-
cantly attenuated the binding afﬁnity. This result indicates that
two Y652 residues in adjacent subunits contribute to the binding.
The effect of the S624 mutation was small but signiﬁcant com-
pared to F656 and Y652.
Changes in the binding afﬁnity to mutant channels having dif-
ferent residues and different numbers of mutated residues suggest
that both of the ﬂuoroquinolones have a similar interaction with
the hERG channel. The patterns of the concentration-dependent
curves revealed that at least two Tyr652s in the neighboring sub-
units and one or two Phe656s in the diagonal subunits are involved
in the binding both compounds, and Ser624 is also involved, albeit
with a smaller contribution.
Based on the experimental results, docking studies for the com-
pounds were performed. A channel model was constructed by
homology modeling using SCWRL 2.9.15 The transmembrane do-
main of a potassium channel with a known crystal structure16
(MthK; PDBID: 1LNQ) was used as a template, based on the amino
acid sequence alignment by ClustalW 1.6.17 The initial structure of
the hERG model was modiﬁed through energy optimizations with-
out any restraint within 7 Å of Ser624s in the selectivity ﬁlter. The
main chain structure in the selectivity ﬁlter region is collapsed
slightly from the template, mimicking the putative high-afﬁnity
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Figure 2. Proposed binding modes for levoﬂoxacin (A) and sparﬂoxacin (B). The number depicted on the residues indicates the subunit number. The stereo side-views of the
binding site are shown with the front subunit removed.
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drug binding modes were generated for each drug molecule using
Gold 2.1.2.18 The binding modes satisfying the above experimental
results were selected by visual inspection. Energy optimization and
ﬁgure generation were performed by MOE (CCG, Canada).19
The proposed blocking modes are shown in Figure 2, in which
the numbers depicted on the residues indicate the subunit number
of the hERG channel. The model revealed that the two ﬂuoroquin-
olones share similar binding modes, spanning three subunits. The
ﬂuoroquinolone scaffold itself is not involved in the binding, but
the substituents at the 1- and 7-positions (sub1 and sub7; Fig. 2,
the right panels) interact with two neighboring Tyr652s (sub1-
Tyr652(2) and sub7-Tyr652(1)). Hetero atoms on these substitu-
ents were hydrogen-bonded with Ser624 (sub1-Ser624(1)). The
basic part in the substituents at the 7-position becomes bound to
one of the Tyr652s by cation–p interaction (sub7-Tyr652(1)). The
access of the relevant part is likely to be driven towards the bind-
ing site by the weak electric ﬁeld in the pore. The other Tyr652
interacts with the substituents at the 1-position by CH–p (sub1-
Tyr652(2)). The carboxyl group draws close to the Phe656 andTable 1
Experimental pKa values for major ﬂuoroquinolone antibiotics reported in the
literature
Compounds pKa (carboxyl) pKa (amino) hERG IC50 (lM)
Grepaﬂoxacin 7.1a 8.8a 50b
Levoﬂoxacin 5.7a 7.9a 915b
Moxiﬂoxacin 6.4c 9.5c 129b
Sparﬂoxacin 6.3d 8.8d 18b
Ciproﬂoxacin 6.1d 8.7d 966b
Oﬂoxacin 6.1d 8.2d 1420b
Gatiﬂoxacin 6.0d 9.2d 130b
a From Ref. 20.
b From Ref. 9.
c From Ref. 21.
d From Ref. 22.interacts with Phe656 by a comparatively strong, noncanonical
process, such as an OH–p interaction or p–p interaction when it
is in a neutral (protonated) state (COOH-Phe656(3)). These results
indicate that the ﬂuoroquinolone scaffold renders multiple substit-
uents distributed in the binding space with distinct distances.
For another ﬂuoroquinolone, moxiﬂoxacin, Alexandrou et al.
have revealed that the Tyr652 but not Phe656 is involved for the
binding based on the experiments using the homo-tetrameric mu-
tants.11 Even in the absence of the information on the number and
position of contributing residues, here we propose a possible bind-
ing mode of the moxiﬂoxacin based on our model results. The sub-
stituent at 7-position of moxiﬂoxacin is bulkier to that of
levoﬂoxacin and sparﬂoxacin. Once the substituents at 7-position
would bind to Tyr652, the ﬂuoroquinolone scaffold is slightly
shifted its location in the binding space. Thus, the other substitu-
ents are able to interact with another Tyr652 but not with
Phe656. This interpretation is worth examining in future trials.
The pKa values of the major ﬂuoroquinolone antibiotics are
listed in Table 1.9,20–22 The values for the carboxyl group in the
ﬂuoroquinolone family were found to be higher (5.7–7.1) than
those for the usual carboxyl groups (4). Thus, the carboxyl group
in the ﬂuoroquinolone antibiotics is readily protonated compared
to other acidic compounds, leading to a potent interaction with
Phe656. This is in contrast to the effect of the introduction of a car-
boxyl group in other drugs for the purpose of eliminating the side
effect on the hERG channel. In these cases, the introduced carbonyl
group, being charged, makes the compound poorly permeable
across the cell membrane and prevents access to the binding site
in the pore.
The protonated carboxyl groups in ﬂuoroquinolone antibiotics
play a role in providing OH or p groups for the purpose of hERG
blockade. The results in this Letter suggest that the introduction
of a carboxyl group does not always help to eliminate hERG
liability. When the observed pKa value of the carboxyl group is
higher than usual, it may bind the inner pore region of the hERG
channel.
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